Europe Market Research Reports & Industry Analysis

Publications found: 90,468
Sort by:

Television Services: European and Asia-Pacific Outlook 2Q 2013

US$ 3,500.00

... market for consumer TV services in Western Europe, Eastern Europe, and the Asia-Pacific region, including cable, IPTV, and satellite/DTH. It examines service provider activities and ... includes subscriber forecasts through 2017. β€œThe TV service markets in Western Europe, Eastern Europe, and the Asia-Pacific Region are more dynamic than ever before ...

January 2013 62 pages

2013 European Coagulation Testing Market: France, Germany, Italy, Spain, UK Emerging Opportunities and Business Expansion Strategies

US$ 14,800.00

... testing practice during the next five years. New specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, continuing contraction ...

December 2012 500 pages

2013 European Infectious Disease Testing Market: France, Germany, Italy, Spain, UK Emerging Opportunities and Business Expansion Strategies

US$ 14,800.00

... designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies. The report provides market segmentation analysis of over ...

December 2012 1600 pages

European Tumor Marker Testing Market: Innovative Technologies and Emerging Business Opportunities

US$ 14,800.00

... current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles ... antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the European cancer diagnostic ...

December 2012 820 pages

European Microbiology Testing Market: Innovative Technologies and Emerging Business Opportunities

US$ 14,800.00

... profiles of leading suppliers and recent market entrants with innovative technologies and products. The infectious disease testing market is one of the most rapidly ... Among the main driving forces behind the growth of this dynamic market is continuous spread of AIDS, which remains the world’s major health ...

December 2012 1600 pages

European Molecular Diagnostics Market: Innovative Technologies and Emerging Business Opportunities

US$ 14,800.00

... in the molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries ( ... of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, ...

December 2012 970 pages

European Nucleic Acid Testing Market: Innovative Technologies and Emerging Business Opportunities

US$ 14,800.00

... methodologies and instrumentation technologies. Feature comparison of automated and semiautomated analyzers. Sales and market shares of leading suppliers. Over 60 specific opportunities for NAT instruments, test systems, IT and auxiliary products. Profiles of major suppliers, and emerging market ...

December 2012 850 pages

European Transfusion Diagnostics Testing Market: Innovative Technologies and Emerging Business Opportunities

US$ 14,800.00

... entrants identify and evaluate emerging opportunities in the European blood banking market during the next five years, and to assist industry ... market will undergo significant transformation, which will result from the convergence of several trends, including more stringent regulations; advances in diagnostic ...

December 2012 600 pages

European Clinical Chemistry and Immunodiagnostics Markets: Innovative Technologies and Emerging Business Opportunities

US$ 14,800.00

... ; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years. The clinical chemistry and immunodiagnostics markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic ...

December 2012 900 pages

European Flow Cytometry Market: Innovative Technologies and Emerging Business Opportunities

US$ 10,000.00

... placements and installed base by manufacturer and model, as well as sales and market shares of leading instrument and reagents suppliers. This 5-country report will ... in the flow cytometry markets during the next five years. The report explores future marketing and technological trends in five major European ...

December 2012 270 pages

European Hematology and Flow Cytometry Markets: Innovative Technologies and Emerging Business Opportunities

US$ 14,800.00

... and flow cytometry markets during the next five years. The report explores future marketing and technological trends in five major European ... forces regulating systemic diseases, will have a profound impact on the hematology and flow cytometry markets worldwide. New molecular diagnostic and monoclonal ...

December 2012 450 pages

European Hemostasis Testing Market: Innovative Technologies and Emerging Business Opportunities

US$ 14,800.00

... segment, as well as major reagent and instrument suppliers sales and market shares. This comprehensive five-country report is designed to help current ... in five major European countries (France, Germany, Italy, Spain, UK); provides estimates of the test volume, as well as sales and market shares of leading ...

December 2012 500 pages

European Immunodiagnostics Markets: Innovative Technologies and Emerging Business Opportunities

US$ 14,800.00

... emerging during the next five years. The clinical chemistry and immunodiagnostics markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some ...

December 2012 900 pages

European Infectious Disease Testing Market: Innovative Technologies and Emerging Business Opportunities

US$ 14,800.00

... companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business ... the main driving forces behind the growth of this dynamic market is continuous spread of AIDS, which remains the worlds major health ...

December 2012 1600 pages

European Blood Banking Market: Innovative Technologies and Emerging Business Opportunities

US$ 14,800.00

... entrants identify and evaluate emerging opportunities in the European blood banking market during the next five years, and to assist industry ... systems, as well as auxiliary products, such as specimen preparation devices, controls, calibrators, and innovative IT applications. Contains 600 pages and 170 tables ...

December 2012 600 pages

Key Smartphone Mobile Data Pricing Trends in Europe

US$ 1,999.00

... the 41 MNOs included in the report Orange, SFR, Bouygues Telecom, Free Mobile (France) Telekom, Vodafone, Telefonica O2, E-Plus (Germany) Vodafone, Telefonica O2, H3G, ... would like to offer a bundle of the new report 'Key Smartphone Mobile Data pricing trends in Europe' and and the 'Global Voice and Data ...

December 2012 -

Specialty Chemicals Industry in Europe

US$ 500.00

... billion in 2007. Aruvian's R'search’s report Specialty Chemicals Industry in Europe researches the characteristics of the European Specialty Chemicals industry and the segments which, as a ... , and the United Kingdom, the biggest specialty chemicals markets in Europe. The report delves deeper into the industry ...

December 2012 150 pages

European Cancer Diagnostics Market: Innovative Technologies and Emerging Business Opportunities

US$ 14,800.00

... report identifies and evaluates major business opportunities emerging in the cancer diagnostics market during the next five years; examines trends in France, ... disease. During the next five years, the European cancer diagnostic testing market is promising to be an exciting, dynamic and rapidly expanding field. ...

December 2012 820 pages

2012 European Connector Market Handbook

US$ 3,950.00

Bishop and Associates has just released the 2012 edition of the European Connector Market Handbook. This comprehensive six-chapter, 254-page ... sector and product category and by 19 countries. Included is a complete chapter on connector industry results by country, equipment sector and product category. Data is ...

November 2012 254 pages

Western Europe (EU-16) In Vitro Diagnostics Market Report & Forecast (2012 – 2015)

US$ 1,200.00

In Western Europe (EU-16) countries major portion of healthcare is borne by the government. These Western Europe (EU-16) countries spend 9 to 11% of their GDP on the healthcare of its citizens. So the...

October 2012 80 pages

A Profile of the Western European Paint Industry, 5th Edition

US$ 4,510.00

IRL is launching the fifth edition of A Profile of the West European Paint Industry. This new edition has been completely updated and revised ... into the decorative and industrial coatings markets for 16 different countries in the Western European region. Primary research for this study has included extensive ...

September 2012 362 pages

The Top 50 Paint & Coatings companies in Europe 2nd Edition

US$ 775.00

... industry review, is pleased to announce the publication of The Top 50 Paint & Coatings Companies in Europe, 2nd Edition. The study revises previous data ... 3M HELIOS GROUP MASCO CORPORATION AB WILH. BECKER ATLAS GROUP NATIONAL PAINTS FACTORIES CO. LTD (SAYEGH GROUP) IVM GROUP TEKNOS REMMERS AG POLISAN ...

August 2012 140 pages

GLOBAL PHARMA SCREEN FOR TOP PICK

US$ 500.00

We recommend MRK and Roche as our Top pick from Global pharma space. NVS as well is interesting, trading at defensive valuations, but except ... they do one could see up to 30-40% upside from current levels. Our screening criteria is based on: Expected News flow from Pipeline and Potential ...

July 2012 21 pages

Booming CCTV Market in Europe Forecast to 2014

US$ 900.00

In the past few years, the rising concerns over security and safety due to increasing terrorist attacks and other criminal activities have led to an enormous growth in the video surveillance market. A...

June 2012 56 pages

Polyurethane Chemicals and Products in EMEA 2012 - Volume 1 Raw Materials

US$ 6,700.00

IAL Consultants is completely updating its in- depth market report on Polyurethane Chemicals and Products in Europe, Middle East and Africa. The new report ... Footwear, Technical Microcellular and Synthetic Leather Resin Binders Forest Products, Rubber Crumb, Foundry Core This latest edition of IAL’s report ...

June 2012 192 pages

Polyurethane Chemicals and Products in EMEA 2012 - Volume 2 Non Foam Products Section 1: Flexible Foam

US$ 5,400.00

IAL Consultants is completely updating its in- depth market report on Polyurethane Chemicals and Products in Europe, Middle East and Africa. The new report ... Footwear, Technical Microcellular and Synthetic Leather Resin Binders Forest Products, Rubber Crumb, Foundry Core This latest edition of IAL’s report ...

June 2012 235 pages

Polyurethane Chemicals and Products in EMEA 2012 - Volume 2 Non-Foam Products Section 2 Rigid Foam

US$ 5,400.00

IAL Consultants is completely updating its in- depth market report on Polyurethane Chemicals and Products in Europe, Middle East and Africa. The new report ... Footwear, Technical Microcellular and Synthetic Leather Resin Binders Forest Products, Rubber Crumb, Foundry Core This latest edition of IAL’s report ...

June 2012 257 pages

Polyurethane Chemicals and Products in EMEA 2012 - Volume 3 Non Foam products Section 2 Adhesives & Sealants

US$ 2,400.00

IAL Consultants is completely updating its in-depth market report on Polyurethane Chemicals and Products in Europe, Middle East and Africa. The new report ... Footwear, Technical Microcellular and Synthetic Leather Resin Binders Forest Products, Rubber Crumb, Foundry Core This latest edition of IAL’s report ...

June 2012 219 pages

Polyurethane Chemicals and Products in EMEA 2012 - Volume 3 Non-Foam Products Section 3 Elastomers

US$ 2,400.00

IAL Consultants is completely updating its in- depth market report on Polyurethane Chemicals and Products in Europe, Middle East and Africa. The new report ... Footwear, Technical Microcellular and Synthetic Leather Resin Binders Forest Products, Rubber Crumb, Foundry Core This latest edition of IAL’s report ...

June 2012 170 pages

Polyurethane Chemicals and Products in EMEA 2012 - Volume 3 Non-Foam Products Section 4 Binders

US$ 1,400.00

IAL Consultants is completely updating its in- depth market report on Polyurethane Chemicals and Products in Europe, Middle East and Africa. The new report ... Footwear, Technical Microcellular and Synthetic Leather Resin Binders Forest Products, Rubber Crumb, Foundry Core This latest edition of IAL’s report ...

June 2012 109 pages

Polyurethane Chemicals and Products in EMEA 2012 - Volume 3 Non-foam Products Section 1 Coatings

US$ 2,400.00

IAL Consultants is completely updating its in-depth market report on Polyurethane Chemicals and Products in Europe, Middle East and Africa. The new report ... Footwear, Technical Microcellular and Synthetic Leather Resin Binders Forest Products, Rubber Crumb, Foundry Core This latest edition of IAL’s report ...

June 2012 204 pages

Polyurethane Chemicals and Products in EMEA 2012 - Volume 4 End-Use markets

US$ 5,400.00

IAL Consultants is completely updating its in- depth market report on Polyurethane Chemicals and Products in Europe, Middle East and Africa. The new report ... Footwear, Technical Microcellular and Synthetic Leather Resin Binders Forest Products, Rubber Crumb, Foundry Core This latest edition of IAL’s report ...

June 2012 194 pages

NOVARTIS - PASPORT Head to Head Study positive: Sandostatin LAR Replacement Ready in active acromegaly

US$ 90.00

Novartis today presented the pasireotide LAR PhIII study data in treatment naΓ―ve ... LAR SOM 230 is also being explored in another Phase 3 study head to head with open label Sandostatin and Lanreotide ATG in patients with ...

May 2012 2 pages

Roche, Merck - DAL-OUTCOMES study terminated - Use any weakness in the stock as an entry point

US$ 90.00

Roche announced discontinuation of DAL-OUTCOME study today due to no meaningful clinical efficacy benefit. Our PT remains unchanged as we ...

May 2012 7 pages

Novartis : Two years safety findings from CATT study favor Lucentis and Eylea, but do pharmacoeconomics justify?

US$ 90.00

The recent two year safety findings from the CATT study in conjunction ... the safety benefits translating into market share gains for either of the drugs. The rate of adverse events at two years, ... are similar to that observed at the end of first year, which shows that there has ...

April 2012 1 pages

Sanofi Q1-2012 results shines on Lantus outperformance, but we see risk to their medium term guidance

US$ 90.00

Sanofi Q1-2012 results shines on Lantus outperformance, but we remain concerned on their medium term guidance SAN posted Q1-2012 results, with sales and business EPS growing 7% and ... guidance, We see potential risk to Lovenox sales growth in Europe from Xarelto / generic copies, slowdown in Lantus sales with ...

April 2012 1 pages

2012 European Clinical Chemistry and Immunodiagnostics Market Outlook: Growth Opportunities and Strategies

US$ 14,799.20

... leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years. The clinical chemistry and immunodiagnostics markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances ...

April 2012 900 pages

Europe LNG Markets to 2020 - Analysis and Forecasts of Terminal wise Capacity and Associated Contracts, LNG Trade movements and Prices

US$ 5,000.00

LNGReports has launched the new comprehensive report on Europe LNG industry outlook to 2020. The report provides profound analysis and complete data on each segment of LNG countries in Europe. It also...

April 2012 250 pages

HARMONY 6 – Albiglutide Non-inferior on Efficacy to Humalog on top of Lantus, but competition better positioned to tap this market

US$ 90.00

GSK reported that topline data from Harmony 6 study met the primary end point. Albiglutide produced clinically significant reductions in HbA1c vs. ... Lantus after 26 wks of treatment. We do not see meaningful potential for albiglutide in the insulin population as the competition (IdegLira and Lyxumia-Lantus ...

April 2012 4 pages

Novartis, GSK - QVA149- Most Advanced once daily LABA+LAMA: Data positive but Competition follows closely

US$ 90.00

... ) exploring the efficacy and safety of QVA149. In the SHINE study (26 wk, n=2100), QVA149 showed statistically superior FEV1 reduction in comparison ... moderate to severe COPD patients. In a smaller BRIGHT study (3 wk), QVA149 demonstrated significant improvement in exercise endurance against placebo and in the ...

April 2012 2 pages

Analyzing the European Footwear Industry

US$ 425.00

... types of footwear produced in Europe are as varied and complementary as Europe’s consumer profile. Aruvian's R'search presents β€œAnalyzing the European Footwear Industry” – a study of the footwear sector in Europe, which assesses ...

April 2012 70 pages

Roche - GSK - EMILIA: TDM1 ready to take over Tykerb

US$ 90.00

Today, Roche and ImmunoGen announced the topline data from EMILIA study ... T-DMI in this indication and this should come at the expense of GSK’s Tykerb, which is the current standard of care in this setting. This ...

March 2012 3 pages

The 2012 European Flow Cytometry Market: France, Germany, Italy, Spain, UK - Emerging Opportunities and Business Expansion Strategies

US$ 10,000.00

... the flow cytometry markets during the next five years. The report explores future marketing and technological trends in five major European ... forecasts, and instrument placements; compares features of major clinical and research flow cytometers; profiles competitors and emerging market entrants; and suggests ...

March 2012 270 pages

Galapagos - Partnership Impact Sustainable?

US$ 140.00

Though deal with Abbott has added credibility to Galapagos’ GLPG0634 (PhII, an oral JAK1 inhibitor), there is still ... by 2014 could elevate GLPG, but our analysis of the impact of catalysts for 2012-13 suggest that …. GLPG0634 will be ... report released on 6th March on GLPG titled β€œPartnership Impact Sustainable?”

March 2012 6 pages

Premium Data Centre Europe 2012 - Pricing, Business Model and Services

US$ 3,355.00

The new Premium Data Centre report provides an analysis of raised floor space, standard rack space pricing and pricing per square metre across the 15 European country markets.The building of dedicate...

March 2012 143 pages

Mobile Network Operator's Trends in Europe

US$ 1,029.00

About this report The Mobile Network Operator Trends report (78 pages in total) is published every six months and the latest edition covers the period June 2011 to December 2011. The report also prov...

March 2012 78 pages

GALAPAGOS - Santa Arrives – Late but With Bounty!

US$ 90.00

Today’s exclusive global agreement of Galapagos’ (GLPG) GLPG0634 (PhII, RA, oral JAK1 inhibitor) with a veteran player in ... , please read our report released on 29th February on GLPG titled β€œSanta Arrives – Late but With Bounty!”

February 2012 3 pages

SANOFI - 4Q Results - No Surprises, Growth going forward will be Challenging

US$ 90.00

Sanofi announced its 4Q-2011 earnings, the revenue and EPS performance ...

February 2012 2 pages

Roche 4Q Results – Inline, while going forward many important studies will further magnify the favorable risk-reward profile

US$ 90.00

Roche 2012 guidance for high single digit EPS growth is below ... . When most peer group companies are struggling to generate growth, Roche has guided for high single digit growth, which the ...

January 2012 3 pages

ROCHE - Erivedge (Vismodegib) approved for Locally Advanced or Metastatic BCC in US

US$ 90.00

... , ROG and Curis jointly announced that the USFDA approved once daily Erivedge, oral, first in class hedgehog inhibitor earlier than ... to be approved for this indication. Erivedge will be available in specialty pharmacies in US within one or two weeks. Roche has the marketing rights for Vismodegib excluding ...

January 2012 5 pages

Filters

Search

Categories

9,489
3,822
567
526
67
27
19
12
6
3
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
363
7
9
1
1
1
8
3
2
1
9
6
3
1
1
1
2
1
1
1,572
2
1
1
1
1
1
1
1
2
1
2
1
3
3
2
2
1
1
1
1
1
1
1
1
1
1
1
1
6
4
1
1
24
8
2
1
2
1
1
5
2
1
2
1
1
1
2
2
6
4
4
3
2
2
2
1
1
2
2
761
321
227
223
175
97
90
86
81
65
61
51
49
48
38
37
33
32
31
30
30
27
26
26
24
24
24
23
21
21
21
20
20
18
18
18
17
17
17
16
16
15
14
14
13
13
12
12
12
12
12
12
12
12
11
9
9
8
8
7
7
7
7
7
6
6
6
6
5
5
5
5
5
5
5
5
5
4
4
4
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
154
149
61
3
2
2
5
4
2
73
4
3
101
2
2
1
4
4
2
2
2
1
1
1
1
1
5
1
2
2
2
2
2
1
1
1
13
3
2
8
4
3
2
1
3
7
8
8
7
5
4
4
2
2
1
1
1
1
1
1
1
1
11
6
6
3
1
2
3
2
3
3
3
2
30
8
7
1
1
1
1
1
4
1
1
5
3
2
2
8
2
1
8
10
8
1
10
39
13
1
10
2
1
6
1
1
1
1
3
1
1
3
3
1
4
7
164
12,693
16
7
1
1
1
269
2
1
1
1
45,532
1
1
2
1
1
1
4
2
1
1
1
2
1
1
1
3
69
5
2
187
52
14
1
21
32
3
2
643
85
37
381
288
243
231
208
163
103
88
85
74
63
55
53
4
2
2
30
15
4
259
119
132
8
1
3
10
4
16
2
15
13
6
3
6
8
1
12
11
1
2
9
18
2
6
6
4
1
5
23
20
5
11
18
3
2
4
1
10
3
8
2,113
4
25
18
4
8
5
15
7
54
29
22
7
2
1
8
7
34
30
15
11
6
4
10
7
17
12
4
589
78
8
4
28
153
50
35
13
58
754
129
23
3
51
26
7
6
25
669
95
938
307
8
11
10

Publishers

66,538
14
845
140
113
69
3
7
891
611
42
2
4,327
1
6
2
10,002
9
17
23
2
1
5
2
135
1,220
416
6
2
104
1
1
198
2
2
62
1
12
1
159
1,813
43
3
2
6
957
1
196
15
14
1,143
6
11
4
4
31
1
23
21
5
3
28
6
10
16
1
62
7
14
10
9
6
1

Regions

90,468

Price

β€”

Date

β€”

Pages

β€”

Offers

1
416